The U.S. District Court for the District of Massachusetts cleared part of the U.S. government’s allegations for trial against Regeneron Pharmaceuticals. The claims assert that the biomedical company reportedly funneled millions of dollars to the Chronic Disease Fund (CDF), an independent charitable foundation, with the intent to subsidize copays for its drug Eylea. The court decided upon the motions for partial summary judgment, concluding that there is sufficient evidence for the government to attempt a demonstration of a causal connection between these donations and kickbacks secured by providers. The presiding court rendered that, “The government is entitled to attempt to prove its case through circumstantial evidence and reasonable inferences.”
Further details regarding the specifics of this trial and the evidence that has been put forth against Regeneron Pharmaceuticals are to be revealed. It’s evident, however, that the court’s present ruling illustrates the government’s alignment with the context and the severity of the charges levied against the pharmaceutical firm.